Johnson & Johnson Could Tap The Huge Diabetes Market With New Drug Approval
Johnson & Johnson has been battling with patent cliffs like many in the industry, but it still is in a better position than many of its peers. Its patent protection on Concerta and Levaquin expired in 2011, while Invega lost patent exclusivity in 2012. All of these patent expirations put nearly $1.5 billion of revenues at risk. However, March could bring some relief to the healthcare company as its blockbuster potential experimental drug, Canagliflozin, is expected to receive FDA approval by the end of the month. After this, the European Medicines Agency approval should not be far away.